ABIONYX Pharma S.A.
ABNX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €40,097 | €37,862 | €48,159 | €60,832 |
| - Cash | €3,235 | €4,104 | €4,046 | €7,935 |
| + Debt | €2,757 | €3,390 | €4,013 | €4,958 |
| Enterprise Value | €39,619 | €37,148 | €48,126 | €57,855 |
| Revenue | €4,600 | €4,640 | €5,252 | €675 |
| % Growth | -0.9% | -11.7% | 678.1% | – |
| Gross Profit | €844 | €618 | €636 | €259 |
| % Margin | 18.3% | 13.3% | 12.1% | 38.4% |
| EBITDA | -€4,928 | -€4,844 | -€4,010 | -€7,418 |
| % Margin | -107.1% | -104.4% | -76.4% | -1,099% |
| Net Income | -€4,400 | -€3,518 | -€4,206 | -€5,822 |
| % Margin | -95.7% | -75.8% | -80.1% | -862.5% |
| EPS Diluted | -0.13 | -0.12 | -0.15 | -0.23 |
| % Growth | -8.3% | 20% | 34.8% | – |
| Operating Cash Flow | -€3,600 | -€3,698 | -€3,359 | -€6,692 |
| Capital Expenditures | €0 | -€130 | -€175 | -€166 |
| Free Cash Flow | -€3,600 | -€3,828 | -€3,534 | -€6,858 |